{"transactions":[{"id":962479,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-12-19T16:17:26.000Z","date":"2025-12-18","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share (\"Common Stock\"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":0.5848,"expiration_date":"2035-12-17","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-25-038443","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774925038443/rdgdoc.xml","form_type":"4"}},{"id":1334441,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2024-12-12T16:35:30.000Z","date":"2024-12-10","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award (the \"Option\") was made in accordance with the terms of the 2020 Equity Incentive Plan (the \"2020 Plan\") of Reviva Pharmaceuticals Holdings, Inc. (the \"Company\"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock (\"Common Stock\") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":2.52,"expiration_date":"2034-12-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-24-037371","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774924037371/rdgdoc.xml","form_type":"4"}},{"id":1731760,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on November 20, 2028, and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":5,"expiration_date":"2028-11-20","underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":1731759,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":2,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2023-11-22T18:28:27.000Z","date":"2023-11-20","kind":"other","planned":false,"acquired":true,"shares":585366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities are included within 585,366 units purchased by Vedanta R2 Partners, LP (\"Vedanta R2\"), an investment vehicle managed by the Reporting Persons, for $5.1249 per unit (each, a \"Unit\"), with such purchase approved by the board of directors of Reviva Pharmaceuticals Holdings, Inc. (the \"Issuer\") as exempt from Section 16(b), to the extent applicable, as an acquisition from the Issuer pursuant to Rule 16b-3(d). Each Unit consists of one pre-funded warrant to purchase one share of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\"), and one common stock warrant to purchase one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta R2. Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Vedanta R2. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners and exercises voting and dispositive power over the securities held by Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":585366,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":585366},"source":{"system":"sec-edgar","filing":"0001493152-23-042540","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000149315223042540/ownership.xml","form_type":"4"}},{"id":1742835,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2023-11-14T16:18:50.000Z","date":"2023-11-13","kind":"grant","planned":false,"acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":8200,"derivative":{"exercise_price":6.04,"expiration_date":"2033-11-12","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001437749-23-031985","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774923031985/rdgdoc.xml","form_type":"4"}},{"id":2118769,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"ten_percent_owner":true}}],"security":"Stock Option (right to buy)","published_at":"2022-11-14T10:34:37.000Z","date":"2022-11-10","kind":"grant","acquired":true,"shares":3900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":3900,"derivative":{"exercise_price":5.13,"expiration_date":"2032-11-09","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":3900},"source":{"system":"sec-edgar","filing":"0001437749-22-027114","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000143774922027114/rdgdoc.xml","form_type":"4"}},{"id":2161581,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":0.0001,"value":51.3834,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161580,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":0.0001,"value":86.9565,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The common stock warrants expire on September 8, 2027 and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":2.4,"expiration_date":"2027-09-08","underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161579,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":513834,"price":2.5299,"value":1299948.6366,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":513834,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":513834},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2161578,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant","published_at":"2022-09-12T16:34:34.000Z","date":"2022-09-08","kind":"purchase","acquired":true,"shares":869565,"price":2.5299,"value":2199912.4935,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners. Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":869565,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":869565},"source":{"system":"sec-edgar","filing":"0001104659-22-099268","document":"tm2225524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465922099268/tm2225524-1_4seq1.xml","form_type":"4"}},{"id":2477718,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-12-10T16:49:00.000Z","date":"2021-12-08","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":5300,"derivative":{"exercise_price":3.78,"expiration_date":"2031-12-07","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001062993-21-012667","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321012667/form4.xml","form_type":"4"}},{"id":2666962,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-16T18:04:37.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the \"2020 Plan\"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan."}],"balance_after":4000,"derivative":{"exercise_price":4.73,"expiration_date":"2031-06-14","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001062993-21-005717","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005717/form4.xml","form_type":"4"}},{"id":2684388,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":299250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684387,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants (right to buy)","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"derivative":{"exercise_price":4.125,"exercise_date":"2021-06-01","expiration_date":"2026-06-01","underlying":"Common Stock","underlying_shares":698250},"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684386,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":399000,"price":3.75,"value":1496250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held directly by Beta Operators Fund, L.P. (\"Beta Operators Fund\"). Vedanta Associates, L.P. (\"Vedanta Associates\") is the general partner of Beta Operators Fund. Vedanta Partners is the general partner of Vedanta Associates, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of Vedanta Associates, Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":399000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2684385,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":108021,"kind":"organization","name":"VEDANTA PARTNERS, LLC","position":1,"cik":"0001502216","reported_name":"VEDANTA PARTNERS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123893,"kind":"organization","name":"Vedanta Associates-R, LP","position":2,"cik":"0001865703","reported_name":"Vedanta Associates-R, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108022,"kind":"organization","name":"VEDANTA ASSOCIATES, L.P.","position":3,"cik":"0001502222","reported_name":"VEDANTA ASSOCIATES, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":123894,"kind":"organization","name":"BETA OPERATORS FUND, L.P.","position":4,"cik":"0001614642","reported_name":"BETA OPERATORS FUND, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":5,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T17:31:45.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":931000,"price":3.75,"value":3491250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The securities were purchased as a unit, with each unit consisting of one share of common stock and one warrant exercisable for 0.75 shares of common stock. The purchase price of each unit was $3.75 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by Vedanta Associates-R, L.P. (\"Vedanta Associates-R\"). Vedanta Partners, LLC (\"Vedanta Partners\") is the general partner of Vedanta Associates-R, and Parag Saxena is the majority member of Vedanta Partners."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Each of Vedanta Partners and Mr. Saxena disclaim beneficial ownership of the securities reported on this Form 4, except to the extent of any pecuniary interest therein."}],"balance_after":931000,"source":{"system":"sec-edgar","filing":"0001062993-21-005353","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000106299321005353/form4.xml","form_type":"4"}},{"id":2931929,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:02:07.000Z","date":"2020-12-15","kind":"other","acquired":false,"shares":540500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"shares","element":"transactionShares","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") agreed to transfer 540,500 warrants to acquire shares of common stock of the issuer to a certain shareholder of the issuer in exchange for such shareholder's agreement to waive and not to exercise any right to redeem or convert shares of the issuer in connection with the Business Combination. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants became exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":0,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":540500},"source":{"system":"sec-edgar","filing":"0001104659-20-139934","document":"tm2039398d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139934/tm2039398d1_4.xml","form_type":"4"}},{"id":2931928,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"grant","acquired":true,"shares":197500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":540500,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":197500},"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2931927,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"other","acquired":true,"shares":343000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"kind","element":"transactionCoding","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer. These warrants were acquired in connection with the issuer's initial public offering. Each whole warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":343000,"derivative":{"exercise_price":11.5,"exercise_date":"2020-12-14","expiration_date":"2025-12-14","underlying":"Common Stock","underlying_shares":343000},"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2931926,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":144382,"kind":"person","name":"Tenzing LLC","position":1,"cik":"0001744957","reported_name":"Tenzing LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":71134,"kind":"person","name":"SAXENA PARAG","position":2,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":144383,"kind":"person","name":"Nayar Rahul","position":3,"cik":"0001744923","reported_name":"Nayar Rahul","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-12-28T20:00:55.000Z","date":"2020-12-14","kind":"grant","acquired":true,"shares":197500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Immediately prior to the consummation of the issuer's initial business combination on December 14, 2020 (the \"Business Combination\"), the issuer changed its corporate structure and domicile by way of continuation from an exempted company incorporated under the laws of the British Virgin Islands to a corporation incorporated under the laws of the State of Delaware (the \"Domestication\"). Pursuant to the Domestication, each outstanding ordinary share of the issuer was converted into one share of the issuer's common stock (the \"common stock\") and each outstanding public warrant of the issuer was converted into a warrant to acquire the common stock. The reporting person held 1,924,250 ordinary shares prior to the Business Combination, which were converted into 1,924,500 shares of common stock upon the Domestication."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"In connection with the consummation of the Business Combination, Tenzing LLC (the \"Reporting Person\" or the \"Sponsor\") elected to convert an aggregate principal amount of $1,975,000 of promissory notes issued to the Sponsor by the issuer into 197,500 units, representing 197,500 shares of common stock and 197,500 warrants to purchase shares of common stock. These warrants underlie units consisting of one share of common stock and one warrant, which were purchased by the Reporting Person for $10.00 per unit on August 20, 2018, pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The Reporting Person acquired beneficial ownership of the warrants in connection with the consummation of the Business Combination on December 14, 2020. Each warrant is exercisable to purchase one share of common stock, subject to adjustment pursuant to the terms of the warrants. The warrants become exercisable on December 14, 2020 and expire at 5:00 p.m., New York City time, on December 14, 2025, or earlier upon their redemption or the liquidation of the issuer pursuant to the terms of the warrants."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"These securities held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chairman, and the managing members of the Sponsor, who have joint voting and dispositive power over the securities held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":2121750,"source":{"system":"sec-edgar","filing":"0001104659-20-139933","document":"tm2039398d2_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920139933/tm2039398d2_4.xml","form_type":"4"}},{"id":2965375,"issuer":{"id":145040,"kind":"organization","name":"Eucrates Biomedical Acquisition Corp.","symbol":"EUCR"},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Ordinary Shares","published_at":"2020-11-27T16:06:19.000Z","date":"2020-11-24","kind":"other","acquired":false,"shares":255094,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reflects the cancellation by the issuer of 255,094 Ordinary Shares, which were automatically surrendered to the issuer for no consideration by the reporting person pursuant to contractual arrangements with the issuer, triggered by the election by the underwriters of the issuer's initial public offering to partially exercise their option to purchase additional units and surrender their right to purchase the remainder of the option units."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reflects the cancellation by the issuer of 255,094 Ordinary Shares, which were automatically surrendered to the issuer for no consideration by the reporting person pursuant to contractual arrangements with the issuer, triggered by the election by the underwriters of the issuer's initial public offering to partially exercise their option to purchase additional units and surrender their right to purchase the remainder of the option units."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares represent ordinary shares held by the issuer's sponsor, Eucrates LLC. The shares held by the sponsor are beneficially owned by each of Parag Saxena and Stelios Papadopoulos, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the sponsor, who have joint voting and dispositive power over the shares held by the sponsor. Mr. Saxena and Mr. Papadopoulos disclaim beneficial ownership over any securities owned by the sponsor in which they do not have any pecuniary interest."}],"balance_after":2619906,"source":{"system":"sec-edgar","filing":"0001104659-20-130017","document":"tm2037212-3_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000110465920130017/tm2037212-3_4.xml","form_type":"4"}},{"id":3827690,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Ordinary Shares","published_at":"2018-09-04T17:00:27.000Z","date":"2018-08-30","kind":"purchase","acquired":true,"shares":33000,"price":10,"value":330000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer in connection with the exercise of the underwriters' over-allotment option pursuant to the issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1924250,"source":{"system":"sec-edgar","filing":"0001144204-18-047839","document":"tv502259_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000114420418047839/tv502259_4.xml","form_type":"4"}},{"id":3834205,"issuer":{"id":8147,"kind":"organization","name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"owners":[{"id":71134,"kind":"person","name":"SAXENA PARAG","position":1,"cik":"0001015823","reported_name":"SAXENA PARAG","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman of the Board"}}],"security":"Ordinary Shares","published_at":"2018-08-24T17:01:12.000Z","date":"2018-08-23","kind":"purchase","acquired":true,"shares":310000,"price":10,"value":3100000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are underlying units (each unit consisting of one ordinary share and one warrant, each warrant exercisable to purchase one share) held by Tenzing LLC (the \"Sponsor\"), acquired pursuant to an amended and restated unit subscription agreement by and between the Sponsor and the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares held by the Sponsor are beneficially owned by Rahul Nayar and Parag Saxena, the issuer's Chief Executive Officer and Chairman, respectively, and the managing members of the Sponsor, who have joint voting and dispositive power over the shares held by the Sponsor. These shares include up to an aggregate of 206,250 ordinary shares subject to forfeiture by the Sponsor to the extent that the underwriters' over-allotment option is not exercised in full. Mr. Nayar and Mr. Saxena disclaim beneficial ownership over any securities owned by the Sponsor in which they do not have any pecuniary interest."}],"balance_after":1891250,"source":{"system":"sec-edgar","filing":"0001144204-18-046298","document":"tv501621_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1015823/000114420418046298/tv501621_4.xml","form_type":"4"}}]}